Compare Merck & Co., Inc. (MRK) vs Shell PLC (SHEL) Price & Performance

Merck & Co., Inc.Trade

Shell PLCTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Shell PLC — how do they compare? Merck & Co., Inc. trades at $126.19 (market cap $307.25B), while Shell PLC trades at $86.69 (market cap $235.24B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Shell PLC pays the higher dividend (3.63%). Which is the better fit depends on your goals.

	MRK	SHEL
Market Cap	$307.25B	$235.24B
Sector	Health	Energy
52-Week High	$129.52	$94.15
52-Week Low	$77.60	$70.31
Enterprise Value	$350.66B	$287.77B
Dividend Yield	2.73%	3.63%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

Shell PLC

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 4 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 1 day agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

SHEL

Shell buys back 184,107 shares as part of its ongoing share repurchase program.Na · 12 hours agoBullish Oil prices top $90 as Strait of Hormuz tensions boost energy stocks, while airlines and housebuilders fall.Proactive Investors · 1 day agoNeutral View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Shell PLC

Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.